{"prompt": "['2016N277425_00', 'CONFIDENTIAL', '2018N377698_00', '201749', '12.6.', 'Appendix 6: Definition of and Procedures for Documenting', 'Medical Device Incidents', '12.6.1.', 'Definitions of a Medical Device Incident', 'The detection and documentation procedures described in this protocol apply to all GSK', 'medical devices provided for use in the study (see Section 6.2 for the list of GSK medical', 'devices).', 'Medical Device Incident Definition:', 'Incident - Any malfunction or deterioration in the characteristics and/or performance', 'of a device, as well as any inadequacy in the labeling or the instructions for use', 'which, directly or indirectly, might lead to or might have led to the death of a', 'patient/user/other persons or to a serious deterioration in their state of health.', 'Not all incidents lead to death or serious deterioration in health. The non-occurrence', 'of such a result might have been due to other fortunate circumstances or to the', 'intervention of health care personnel.', 'It is sufficient that:', 'an incident associated with a device happened and', 'the incident was such that, if it occurred again, might lead to death or a serious', 'deterioration in health.', 'A serious deterioration in state of health can include:', 'life-threatening illness', 'permanent impairment of body function or permanent damage to a body structure', 'a condition necessitating medical or surgical intervention to prevent one of the', 'above', 'fetal distress, fetal death or any congenital abnormality or birth defects', 'Examples of incidents', 'a patient, user, care giver or professional is injured as a result of a medical device', 'failure or its misuse', \"a patient's treatment is interrupted or compromised by a medical device failure\", 'misdiagnosis due to medical device failure leads to inappropriate treatment', \"a patient's health deteriorates due to medical device failure\", '85']['2016N277425_00', 'CONFIDENTIAL', '2018N377698_00', '201749', '12.6.2.', 'Documenting Medical Device Incidents', 'Medical Device Incident Documenting:', 'Any medical device incident occurring during the study will be documented in the', \"subject's medical records, in accordance with the investigator's normal clinical\", 'practice, and on the appropriate form.', 'For incidents fulfilling the definition of an AE or an SAE, the appropriate AE/SAE', 'CRF page will be completed as described in Appendix 4.', 'The form will be completed as thoroughly as possible and signed by the investigator', 'before transmittal to GSK.', 'It is very important that the investigator provides his/her assessment of causality to', 'the medical device provided by GSK at the time of the initial report, and describes', 'any corrective or remedial actions taken to prevent recurrence of the incident.', 'A remedial action is any action other than routine maintenance or servicing of a', 'device where such action is necessary to prevent recurrence of an incident. This', 'includes any amendment to the design to prevent recurrence.', '86']['2016N277425_00', 'CONFIDENTIAL', '2018N377698_00', '201749', '12.7.', 'Appendix 7: Modified List of Highly Effective Methods for', 'Avoiding Pregnancy in FRP and Collection of Pregnancy', 'Information', '12.7.1.', 'Modified List of Highly Effective Methods for Avoiding Pregnancy', 'in Females of Reproductive Potential (FRP)', 'The list does not apply to FRP with same sex partners or for subjects who are and will', 'continue to be abstinent from penile-vaginal intercourse on a long term and persistent', 'basis, when this is their preferred and usual lifestyle. Periodic abstinence (e.g. calendar,', 'ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable', 'methods of contraception.', '1.', 'Contraceptive subdermal implant', '2.', 'Intrauterine device or intrauterine system', '3. Combined estrogen and progestogen oral contraceptive [Hatcher, 2011]', '4.', 'Injectable progestogen [Hatcher, 2011]', '5.', 'Contraceptive vaginal ring [Hatcher, 2011]', '6.', 'Percutaneous contraceptive patches [Hatcher, 2011]', '7. Male partner sterilization with documentation of azoospermia prior to the female', \"subject's entry into the study, and this male is the sole partner for that subject\", '[Hatcher, 2011]. The documentation on male sterility can come from the site', \"personnel's: review of subject's medical records, medical examination and/or semen\", 'analysis, or medical history interview provided by her or her partner.', 'These allowed methods of contraception are only effective when used consistently,', 'correctly and in accordance with the product label. The investigator is responsible for', 'ensuring that subjects understand how to properly use these methods of contraception.', '12.7.2.', 'Collection of Pregnancy Information', 'Investigator will collect pregnancy information on any female subject, who becomes', 'pregnant while participating in this study', 'Information will be recorded on the appropriate form and submitted to GSK within 2', \"weeks of learning of a subject's pregnancy.\", 'Subject will be followed to determine the outcome of the pregnancy. The', 'investigator will collect follow up information on mother and infant, which will be', 'forwarded to GSK. Generally, follow-up will not be required for longer than 6 to 8', 'weeks beyond the estimated delivery date.', 'Any termination of pregnancy will be reported, regardless of fetal status (presence or', 'absence of anomalies) or indication for procedure.', 'While pregnancy itself is not considered to be an AE or SAE, any pregnancy', 'complication or elective termination of a pregnancy will be reported as an AE or', 'SAE.', '87']\n\n###\n\n", "completion": "END"}